Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | GLB1 | P16278 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12347904 | 1.00 | CA2 (0.35) | CA2CA1CA9GLB1ALDH1A1 | |
| SCHEMBL29546906 | 1.00 | CA2 (0.35) | CA2CA1CA9GLB1ALDH1A1 | |
| SCHEMBL24256838 | 0.87 | CA2 (0.33) | CA2CA1CA9GLB1 | |
| SCHEMBL26900900 | 0.87 | CA2 (0.33) | CA2CA1CA9GLB1 | |
| SCHEMBL26899746 | 0.87 | CA2 (0.33) | CA2CA1CA9GLB1 | |
| SCHEMBL10118193 | 0.82 | PI4KA (0.38) | CA2CA1CA9GLB1ALDH1A1 | |
| SCHEMBL12803859 | 0.82 | PI4KA (0.38) | CA2CA1CA9GLB1ALDH1A1 | |
| SCHEMBL7213366 | 0.82 | PI4KA (0.38) | CA2CA1CA9GLB1ALDH1A1 | |
| SCHEMBL4308897 | 0.82 | PI4KA (0.38) | CA2CA1CA9GLB1ALDH1A1 | |
| SCHEMBL16707279 | 0.82 | PI4KA (0.38) | CA2CA1CA9GLB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI SA (FR) | 2024-03-21 | — | — | US | disclosed |
| EP-4232455-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | Sanofi (FR) | 2023-08-30 | — | — | EP | disclosed |
| WO-2022084331-A2 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | SANOFI (FR) | 2022-04-28 | — | — | WO | disclosed |
| US-20110201794-A1 | Disaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2011-08-18 | — | — | US | disclosed |
| US-7875707-B2 | combinatorial libraries; lipid solubility; solid phase synthesis | ALCHEMIA LIMITED (AU) | 2011-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201794-A1 | Disaccharides for drug discovery | UGCG, STT3A, DDOST | CA2 3437/4885CA1 2870/4885CA9 1475/4885 |
| US-20240092819-A1 | NOVEL LIGANDS FOR ASIALOGLYCOPROTEIN RECEPTOR | ASGR1, HAVCR2, SIGLEC7 | CA2 4829/4885CA1 4710/4885CA9 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.